Pharmacologic management of cancer pain

Journal of the American Osteopathic Association

Volumn 105, Issue 11 SUPPL. 5, 2005, Pages

  Pharo, Gregory H ^a,b,c   Zhou, Linqiu ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Jefferson Pain Center   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; CYCLOOXYGENASE 2 INHIBITOR; DESIPRAMINE; DOXEPIN; IMIPRAMINE; KETAMINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; ROFECOXIB; VALDECOXIB; ANALGESIC AGENT; ANTICONVULSIVE AGENT; CORTICOSTEROID; LOCAL ANESTHETIC AGENT; NARCOTIC ANALGESIC AGENT;

ADJUVANT THERAPY; CANCER PAIN; HUMAN; REVIEW; WORLD HEALTH ORGANIZATION; NEOPLASM; PAIN; PSYCHOLOGICAL ASPECT;

ADRENAL CORTEX HORMONES; ANALGESICS; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANESTHETICS, LOCAL; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; HUMANS; KETAMINE; NEOPLASMS; PAIN;

EID: 33644873527     PISSN: 00986151     EISSN: 00986151     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer Statistics, 2004. CA: Cancer J Clin. 2004;54:8-29.
2. A. Wingo PA, Cardinex CJ, Landis SH, Greenlee RT, Ries LA, Anderson RN. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97(12 suppl):3133-1998. Erratum in Cancer. 2005;103(12)2658.
3. Fine PG. The evolving and important role of anesthesiology in palliative care. Anesth Analg. 2005;100:183-188.
4. Abrahm JL. Promoting symptom control in palliative care. Semin Oncol Nurs. 1998;14(2):95-109.
5. Mercadante S, Fulfaro F. World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol. 2005;16(suppl 4):iv132-iv135.
6. Wootton M. Morphine is not the only analgesic in palliative care: literature review. J Adv Nurs. 2004;45:527-532.
7. McNicol E, Strassels S, Goudas L, Lau J, Carr D. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. J Clin Oncol. 2004;22:1975-1992.
8. Haegerstam GAT. Pathophysiology of bone pain: a review. Acta Orthop Scand. 2001;72:308-317.
9. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349:1943-1953.
10. Silvestri GA, Sherman C, Williams T, Leong SS, Flume P, Turrisi A. Caring for the dying patient with lung cancer. Chest. 2002;122:1028-1036.
11. Patrignani P, Tacconelli S, Scuilla MG, Capone ML. New insights into COX-2 biology and inhibition. Brain Res Brain Res Rev. 2005;48:352-359.
12. Stockler M, Vardy J, Pillai A. Warr, D. Acetaminophen (paracetomal) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled crossover trial. J Clin Oncol. 2004;22:3389-3394.
13. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081-1091.
14. Carr DB, Goudas LC, Balk EM, Bloch R, Ionnidis JP, Lau J. Evidence report on the treatment of pain in cancer patients. J Nat Cancer Inst Monogr. 2004;32:23-31.
15. Mercadante S, Ferrera P, Villari P, Casuccio A. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol. 2005;23:5229-5234.
16. Bailey PL, Egan TD, Stanley TH. Intravenous opioid anesthetic. In: Miller RD, ed. Anesthesia. 5th Ed. Philadelphia, Pa: Churchill Livingstone; 2000:273-386.
17. Manfredonia JF. Prescribing methadone for pain management in end-of-life care. J Am Osteopath. 2005;105(suppl 1):S11-S18.
18. Cady J. Understanding opioid tolerance in cancer pain. Oncol Nurs Forum. 2001;28:1561-1568.
19. Guo-xi X, Palmer PP. RGS proteins: new players in the field of opioid signaling and tolerance mechanisms. Anesth Analg. 2005;100:1034-1042.
20. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003;97:1108-1116.
21. Hocking G, Cousins M. Ketamine in chronic pain management: an evidence-based review. Anesth Analg. 2003;97:1108-1116.
22. Shimoyama N, Shimoyama M, Inturrisi CE, Elliot KJ. Ketamine attenuates and reverses morphine tolerance in rodents. Anesthesiology. 1996;85:1357-1366.
23. Stoelting RK. Nonbarbiturate induction agents. In: Stoelting RK, ed. Pharmacology and Physiology in Anesthesia Practice. Philadelphia, Pa: JB Lippincott Co; 1987:134-5.
24. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004;9:571-591.
25. Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician. 2005;71:483-490.
26. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Ivengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109-18.
27. Adriaensen H, Plaghki K, Mathieu C, Joffroy A, Vissers K. Critical review of oral drug treatments for diabetic neuropathic pain - clinical outcomes based on efficacy and safety data from placebo-controlled and direct comparative studies. Diabetes Metab Res Rev. 2005;21(3):231-240.
28. Dunteman ED. Levetiracetam as an adjunctive analgesic in neoplastic plexopathies: case series and commentary. J Pain Palliat Care Pharmacother. 2005;19(1):35-43.
29. Demoly P, Chung KF. Pharmacology of corticosteroids. Respir Med. 1998;92:385-394.
30. Gordon DH. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clin Breast Cancer. 2005;6(2):125-131.
31. + channel immunolocalization in peripheral mammaliam axons and changes following nerve injuury and neuroma formation. J Neurosci. 1993;13:76-92.